Indeed, the downregulation of PRMT1 in both cervical cancer and ovarian cancer cells improved their sensitivity to cisplatin treatment (Matsubara et al., 2021; Shimomura et al., 2021). This evidence concerns the gene PRMT1 and ovarian carcinoma.